Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2099208 | 0.85 | CES2 (0.42) | MAPTALDH1A1KMT2APOLBRAB9A | |
| SCHEMBL6498922 | 0.84 | KMT2A (0.55) | MAPTALDH1A1KMT2APOLBRAB9A | |
| SCHEMBL6695151 | 0.84 | ALDH1A1 (0.36) | MAPTALDH1A1KMT2A | |
| Bromide SCHEMBL6282381 | 0.83 | KMT2A (0.53) | MAPTALDH1A1KMT2APOLBRAB9A | |
| SCHEMBL2935375 | 0.80 | LMNA (0.36) | MAPTALDH1A1KMT2APOLBHPGD | |
| SCHEMBL7142799 | 0.80 | NAMPT (0.49) | MAPTALDH1A1KMT2AKCNA5TBXAS1 | |
| SCHEMBL2936991 | 0.79 | CA12 (0.37) | MAPTALDH1A1KMT2A | |
| SCHEMBL6779593 | 0.79 | ALDH1A1 (0.49) | MAPTALDH1A1KMT2APOLBRAB9A | |
| Bromide SCHEMBL6276160 | 0.79 | NAMPT (0.48) | MAPTALDH1A1KMT2AKCNA5TBXAS1 | |
| SCHEMBL7149156 | 0.78 | CYP17A1 (0.49) | MAPTALDH1A1KMT2ATBXAS1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044226-A1 | Estrogen receptor modulators | DININNO FRANK P (US) | 2004-03-04 | — | — | US | disclosed |
| EP-1333827-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1328522-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002032373-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032377-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044226-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | MAPT 1213/4885ALDH1A1 1455/4885KMT2A 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.